These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 25514659)

  • 21. Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone.
    Inden M; Kitamura Y; Takeuchi H; Yanagida T; Takata K; Kobayashi Y; Taniguchi T; Yoshimoto K; Kaneko M; Okuma Y; Taira T; Ariga H; Shimohama S
    J Neurochem; 2007 Jun; 101(6):1491-1504. PubMed ID: 17459145
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of centrophenoxine against rotenone-induced oxidative stress in an animal model of Parkinson's disease.
    Verma R; Nehru B
    Neurochem Int; 2009 Nov; 55(6):369-75. PubMed ID: 19375462
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pigment epithelium derived factor (PEDF) is neuroprotective in two in vitro models of Parkinson's disease.
    Falk T; Zhang S; Sherman SJ
    Neurosci Lett; 2009 Jul; 458(2):49-52. PubMed ID: 19442875
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diffusion kurtosis imaging detects the time-dependent progress of pathological changes in the oral rotenone mouse model of Parkinson's disease.
    Khairnar A; Ruda-Kucerova J; Arab A; Hadjistyllis C; Sejnoha Minsterova A; Shang Q; Chovsepian A; Drazanova E; Szabó N; Starcuk Z; Rektorova I; Pan-Montojo F
    J Neurochem; 2021 Aug; 158(3):779-797. PubMed ID: 34107061
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson's disease model.
    Tapias V; Cannon JR; Greenamyre JT
    J Neurosci Res; 2010 Feb; 88(2):420-7. PubMed ID: 19681169
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ameliorative effect of Sida cordifolia in rotenone induced oxidative stress model of Parkinson's disease.
    Khurana N; Gajbhiye A
    Neurotoxicology; 2013 Dec; 39():57-64. PubMed ID: 23994302
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sesamol and naringenin reverse the effect of rotenone-induced PD rat model.
    Sonia Angeline M; Sarkar A; Anand K; Ambasta RK; Kumar P
    Neuroscience; 2013 Dec; 254():379-94. PubMed ID: 24070629
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Parkinson's disease: genetics and pathogenesis.
    Shulman JM; De Jager PL; Feany MB
    Annu Rev Pathol; 2011; 6():193-222. PubMed ID: 21034221
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolic dysfunctions in the intranigral rotenone model of Parkinson's disease.
    Chuproski AP; Azevedo EM; Ilkiw J; Miloch J; Lima MMS
    Exp Brain Res; 2023 May; 241(5):1289-1298. PubMed ID: 37000202
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Selective stimulations and lesions of the rat brain nuclei as the models for research of the human sleep pathology mechanisms].
    Šaponjić J
    Glas Srp Akad Nauka Med; 2011; (51):85-97. PubMed ID: 22165729
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose-dependent loss of motor function after unilateral medial forebrain bundle rotenone lesion in rats: a cautionary note.
    Klein A; Gidyk DC; Shriner AM; Colwell KL; Tatton NA; Tatton WG; Metz GA
    Behav Brain Res; 2011 Sep; 222(1):33-42. PubMed ID: 21419806
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Using Rotenone to Model Parkinson's Disease in Mice: A Review of the Role of Pharmacokinetics.
    Innos J; Hickey MA
    Chem Res Toxicol; 2021 May; 34(5):1223-1239. PubMed ID: 33961406
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tryptophan in the diet ameliorates motor deficits in a rotenone-induced rat Parkinson's disease model via activating the aromatic hydrocarbon receptor pathway.
    Wang Y; Chen S; Tan J; Gao Y; Yan H; Liu Y; Yi S; Xiao Z; Wu H
    Brain Behav; 2021 Aug; 11(8):e2226. PubMed ID: 34105899
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of caffeine in Parkinson's disease: from neuroprotection to the management of motor and non-motor symptoms.
    Prediger RD
    J Alzheimers Dis; 2010; 20 Suppl 1():S205-20. PubMed ID: 20182024
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Behavioural and neural deficits induced by rotenone in the pond snail Lymnaea stagnalis. A possible model for Parkinson's disease in an invertebrate.
    Vehovszky A; Szabó H; Hiripi L; Elliott CJ; Hernádi L
    Eur J Neurosci; 2007 Apr; 25(7):2123-30. PubMed ID: 17439496
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Controversies on new animal models of Parkinson's disease pro and con: the rotenone model of Parkinson's disease (PD).
    Schmidt WJ; Alam M
    J Neural Transm Suppl; 2006; (70):273-6. PubMed ID: 17017541
    [TBL] [Abstract][Full Text] [Related]  

  • 37. p38(MAPK)/p53-Mediated Bax induction contributes to neurons degeneration in rotenone-induced cellular and rat models of Parkinson's disease.
    Wu F; Wang Z; Gu JH; Ge JB; Liang ZQ; Qin ZH
    Neurochem Int; 2013 Sep; 63(3):133-40. PubMed ID: 23714208
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neurotoxicant-induced animal models of Parkinson's disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration.
    Uversky VN
    Cell Tissue Res; 2004 Oct; 318(1):225-41. PubMed ID: 15258850
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overview of mouse models of Parkinson's disease.
    Bobela W; Zheng L; Schneider BL
    Curr Protoc Mouse Biol; 2014 Sep; 4(3):121-39. PubMed ID: 25723963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Parkinson's disease-like motor and non-motor symptoms in rotenone-treated zebrafish.
    Wang Y; Liu W; Yang J; Wang F; Sima Y; Zhong ZM; Wang H; Hu LF; Liu CF
    Neurotoxicology; 2017 Jan; 58():103-109. PubMed ID: 27866991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.